Elixir Medical Highlights the Data from INFINITY-SWEDEHEART Study of DynamX Coronary Bioadaptor System for Coronary Artery Disease at ESC 2024
Shots:
- The registry-based INFINITY-SWEDEHEART study assesses DynamX Bioadaptor vs Resolute Onyx among 2,400 individuals in ratio 1:1 across Sweden
- Study depicted a reduction of 0.2% vs 1.3% in target lesion failure (TLF) after 6mos. & 2.35% vs 2.77% after 12mos. as well as a reduction of 0.6% vs 1.8% in target vessel failure (TVF) after 6mos. & 3.03% vs 3.52% after 12mos.
- The system works in 3 phases: Locked phase (establishes max. flow lumen to restore blood flow), Unlocked/Separation phase (helical strands get separated post 6mos., allowing adaptive vessel remodeling) & Adaptive dynamic support phase (separated strands provide support to restore vessel pulsatility, compliance & adaptive blood flow)
Ref: Elixir Medical | Image: Elixir Medical
Related News:- Medinol’s EluNIR-PERL Drug-Eluting Coronary Stent System Receives the US FDA’s Approval to Treat Coronary Artery Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
